MX2015009276A - Donadores de nitroxilo con indice terapeutico mejorado. - Google Patents

Donadores de nitroxilo con indice terapeutico mejorado.

Info

Publication number
MX2015009276A
MX2015009276A MX2015009276A MX2015009276A MX2015009276A MX 2015009276 A MX2015009276 A MX 2015009276A MX 2015009276 A MX2015009276 A MX 2015009276A MX 2015009276 A MX2015009276 A MX 2015009276A MX 2015009276 A MX2015009276 A MX 2015009276A
Authority
MX
Mexico
Prior art keywords
therapeutic index
improved therapeutic
compounds
nitroxyl donors
pharmaceutical compositions
Prior art date
Application number
MX2015009276A
Other languages
English (en)
Inventor
Stephen Martin Courtney
John P Toscano
Frederick Arthur Brookfield
Lisa Marie Frost
Vincent Jacob Kalish
Original Assignee
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardioxyl Pharmaceuticals Inc filed Critical Cardioxyl Pharmaceuticals Inc
Publication of MX2015009276A publication Critical patent/MX2015009276A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/64—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La materia objeto que se describe proporciona compuestos derivados de hidroxilamina N-sustituidos, composiciones farmacéuticas y kits que comprenden a estos compuestos, y métodos de uso de estos compuestos o composiciones farmacéuticas. En particular, la materia objeto que se describe proporciona métodos de uso de estos compuestos o composiciones farmacéuticas para tratar fallo cardíaco.
MX2015009276A 2013-01-18 2014-01-17 Donadores de nitroxilo con indice terapeutico mejorado. MX2015009276A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361754237P 2013-01-18 2013-01-18
US201361782781P 2013-03-14 2013-03-14
PCT/US2014/012085 WO2014113696A1 (en) 2013-01-18 2014-01-17 Nitroxyl donors with improved therapeutic index

Publications (1)

Publication Number Publication Date
MX2015009276A true MX2015009276A (es) 2015-10-30

Family

ID=50064795

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015009269A MX363843B (es) 2013-01-18 2014-01-17 Composiciones farmaceuticas que comprenden donadores de nitroxilo.
MX2015009276A MX2015009276A (es) 2013-01-18 2014-01-17 Donadores de nitroxilo con indice terapeutico mejorado.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2015009269A MX363843B (es) 2013-01-18 2014-01-17 Composiciones farmaceuticas que comprenden donadores de nitroxilo.

Country Status (28)

Country Link
US (13) US8987326B2 (es)
EP (5) EP2945621B1 (es)
JP (5) JP6449171B2 (es)
KR (2) KR102177899B1 (es)
CN (4) CN110179777B (es)
AU (5) AU2014207408C1 (es)
BR (2) BR112015017241B1 (es)
CA (2) CA2898445C (es)
CY (3) CY1120535T1 (es)
DK (3) DK3284463T3 (es)
ES (4) ES2882279T3 (es)
HK (3) HK1216858A1 (es)
HR (3) HRP20180121T1 (es)
HU (3) HUE046722T2 (es)
IL (4) IL239906B (es)
LT (3) LT2945620T (es)
MX (2) MX363843B (es)
NZ (4) NZ748769A (es)
PL (3) PL3284463T3 (es)
PT (3) PT2945621T (es)
RS (3) RS59434B1 (es)
RU (3) RU2018143994A (es)
SG (6) SG10201802855TA (es)
SI (3) SI3284463T1 (es)
TR (1) TR201802211T4 (es)
TW (3) TWI619491B (es)
WO (2) WO2014113696A1 (es)
ZA (2) ZA201505090B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2489350T3 (en) 2006-03-17 2014-03-03 Univ Johns Hopkins Med N-hydroxylsulfonamidderivater as new physiologically useful nitroxyldonorer
EP2776402B1 (en) 2011-10-17 2017-07-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
TWI619491B (zh) 2013-01-18 2018-04-01 卡爾迪奧克斯爾製藥公司 包含硝醯基予體的醫藥組合物
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
WO2015183839A1 (en) 2014-05-27 2015-12-03 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
CN108349911B (zh) 2015-09-07 2022-05-13 浙江华海药业股份有限公司 可释放一氧化氮的前药分子
KR20180063326A (ko) 2015-10-19 2018-06-11 카르디옥실 파마슈티칼스 인코포레이티드 니트록실 공여자로서의 피라졸론 유도체
WO2017070084A1 (en) 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
KR20190070912A (ko) 2016-07-28 2019-06-21 더 존스 홉킨스 유니버시티 O-치환된 히드록삼산
MX2019008000A (es) * 2017-01-03 2019-11-05 Cardioxyl Pharmaceuticals Inc Metodo de administracion de compuestos donadores de nitroxilo.
AU2018254743B2 (en) * 2017-04-18 2024-04-11 Genfit Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US1021340A (en) 1911-10-14 1912-03-26 William A Scott Means for attaching binding-posts to dry batteries.
US3751255A (en) 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0828240B2 (ja) 1990-05-25 1996-03-21 矢崎総業株式会社 電線相互の圧着接続構造及び圧着接続方法
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
JPH09507672A (ja) * 1994-01-19 1997-08-05 ビイク ネダーラント ベスローテン フェンノートシャップ ニトロキシ基含有ベンジルアミン誘導体及び循環器疾患並びに眼内圧増加の治療のためのその使用
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
JPH10142729A (ja) 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
TR200001121T2 (tr) 1997-10-24 2000-09-21 Shionogi & Co., Ltd. Antiromatizmal madde.
DE69906397T2 (de) * 1998-01-16 2004-02-19 F. Hoffmann-La Roche Ag Benzosulfonderivate
WO1999063385A1 (en) 1998-06-04 1999-12-09 Board Of Regents, The University Of Texas System Digital optical chemistry micromirror imager
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CN1163223C (zh) 1998-07-28 2004-08-25 田边制药株式会社 肠内目标部位释放型制剂
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
HUP0303857A3 (en) * 2000-12-13 2007-07-30 Wyeth Corp Heterocyclic sulifonamide inhibitors of beta amyloid production
EP1219306A1 (en) * 2000-12-29 2002-07-03 Nicox S.A. Compositions comprising cyclodextrins and NO- releasing drugs
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090281067A1 (en) 2004-01-30 2009-11-12 The John Hopkins University Nitroxyl progenitor compounds and methods of use
WO2006086188A2 (en) 2005-01-31 2006-08-17 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
WO2007002444A1 (en) 2005-06-23 2007-01-04 Johns Hopkins University Thiol-sensitive positive inotropes
DK2489350T3 (en) 2006-03-17 2014-03-03 Univ Johns Hopkins Med N-hydroxylsulfonamidderivater as new physiologically useful nitroxyldonorer
US7696373B2 (en) 2006-04-13 2010-04-13 Wake Forest University Health Sciences C-nitroso-derived nitroxyl donors
BRPI0817562A2 (pt) * 2007-09-26 2017-05-02 Cardioxyl Pharmaceuticals Inc derivados de n-hidroxilsulfonamida como novos doadores de niltroxil fisiologicamente úteis
US8318705B2 (en) 2008-05-07 2012-11-27 Cardioxyl Pharmaceuticals, Inc. Nitroso compounds as nitroxyl donors and methods of use thereof
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
JP5826762B2 (ja) * 2009-12-07 2015-12-02 ザ ジョンズ ホプキンス ユニバーシティ Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体
IN2012DN05028A (es) * 2009-12-07 2015-10-23 Univ Johns Hopkins
EP2776402B1 (en) 2011-10-17 2017-07-26 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as hno donors
JP6306602B2 (ja) 2012-11-01 2018-04-04 ザ ジョンズ ホプキンス ユニバーシティ 分子内環化−脱離による制御されたｈｎｏ放出
TWI619491B (zh) 2013-01-18 2018-04-01 卡爾迪奧克斯爾製藥公司 包含硝醯基予體的醫藥組合物
ES2734060T3 (es) 2014-01-17 2019-12-04 Cardioxyl Pharmaceuticals Inc Donadores de nitroxilo de N-hidroximetanosulfonamida
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives

Also Published As

Publication number Publication date
HUE036589T2 (hu) 2018-07-30
TW201442702A (zh) 2014-11-16
HK1216857A1 (zh) 2016-12-09
CY1122177T1 (el) 2020-11-25
RU2018143994A (ru) 2019-01-16
JP2019172682A (ja) 2019-10-10
JP6533159B2 (ja) 2019-06-19
CA2898445C (en) 2022-05-03
AU2017200147A1 (en) 2017-02-02
CY1120535T1 (el) 2019-07-10
BR112015017251A2 (pt) 2017-07-11
TWI619491B (zh) 2018-04-01
US20150175566A1 (en) 2015-06-25
ZA201604798B (en) 2018-01-31
EP3427728A1 (en) 2019-01-16
TWI686193B (zh) 2020-03-01
IL259233B (en) 2019-10-31
EP3427728B1 (en) 2021-07-07
US20170151210A1 (en) 2017-06-01
US20200163929A1 (en) 2020-05-28
US10213408B2 (en) 2019-02-26
TR201802211T4 (tr) 2018-03-21
LT2945621T (lt) 2019-01-10
LT3284463T (lt) 2019-11-11
IL239952B (en) 2018-05-31
EP2945620A1 (en) 2015-11-25
RU2676277C2 (ru) 2018-12-27
SG10201802855TA (en) 2018-05-30
CA2898445A1 (en) 2014-07-24
ES2751922T3 (es) 2020-04-02
CN105073105A (zh) 2015-11-18
US20240066002A1 (en) 2024-02-29
SI2945621T1 (sl) 2019-01-31
US8987326B2 (en) 2015-03-24
SI2945620T1 (en) 2018-01-31
US11786501B2 (en) 2023-10-17
AU2018241168B2 (en) 2020-04-02
ES2882279T3 (es) 2021-12-01
EP3284463B1 (en) 2019-07-24
IL258882A (en) 2018-06-28
JP2016505044A (ja) 2016-02-18
CN108610312A (zh) 2018-10-02
MX363843B (es) 2019-04-05
BR112015017251B1 (pt) 2021-10-26
BR112015017251A8 (pt) 2019-10-29
KR20150107853A (ko) 2015-09-23
KR102277165B1 (ko) 2021-07-14
RS56968B1 (sr) 2018-05-31
SG11201505568PA (en) 2015-09-29
US20200121633A1 (en) 2020-04-23
DK2945621T3 (en) 2019-02-11
KR20150108879A (ko) 2015-09-30
SG10201913441RA (en) 2020-03-30
JP6311038B2 (ja) 2018-04-11
NZ748769A (en) 2020-05-29
JP2017125015A (ja) 2017-07-20
TW201446242A (zh) 2014-12-16
MX2015009269A (es) 2015-10-30
PL2945621T3 (pl) 2019-05-31
JP6656345B2 (ja) 2020-03-04
AU2014207408A1 (en) 2015-08-13
US9586896B2 (en) 2017-03-07
EP3284463A1 (en) 2018-02-21
CA2898443C (en) 2022-05-31
AU2014207404A1 (en) 2015-08-13
NZ709985A (en) 2020-05-29
JP2019089764A (ja) 2019-06-13
IL259233A (en) 2018-07-31
HRP20191919T8 (hr) 2021-10-01
PT2945621T (pt) 2019-01-21
TW201934120A (zh) 2019-09-01
US10792273B2 (en) 2020-10-06
BR112015017241A2 (pt) 2017-07-11
WO2014113696A1 (en) 2014-07-24
US11273143B2 (en) 2022-03-15
PL2945620T3 (pl) 2018-03-30
HUE041861T2 (hu) 2019-06-28
US10517847B2 (en) 2019-12-31
RS59434B1 (sr) 2019-11-29
HUE046722T2 (hu) 2020-03-30
PT3284463T (pt) 2019-10-30
RU2015134581A (ru) 2017-02-27
US11304924B2 (en) 2022-04-19
HRP20180121T1 (hr) 2018-02-23
US9156804B2 (en) 2015-10-13
AU2014207404B2 (en) 2017-10-19
EP3567031A1 (en) 2019-11-13
AU2014207408B2 (en) 2018-03-01
CN105142627B (zh) 2019-06-21
ES2705240T3 (es) 2019-03-22
US20150366977A1 (en) 2015-12-24
US20160031807A1 (en) 2016-02-04
RU2684916C2 (ru) 2019-04-16
ZA201505090B (en) 2016-10-26
BR112015017241A8 (pt) 2019-10-29
KR102177899B1 (ko) 2020-11-12
IL239952A0 (en) 2015-08-31
JP2016510326A (ja) 2016-04-07
US20180235927A1 (en) 2018-08-23
AU2014207408A8 (en) 2015-08-27
HK1216858A1 (zh) 2016-12-09
SG10201802862WA (en) 2018-05-30
JP6801045B2 (ja) 2020-12-16
AU2014207408C1 (en) 2018-09-06
HK1251170B (zh) 2020-04-09
CN110179777A (zh) 2019-08-30
US9968584B2 (en) 2018-05-15
US20220193026A1 (en) 2022-06-23
US20190224159A1 (en) 2019-07-25
PL3284463T3 (pl) 2019-12-31
JP6449171B2 (ja) 2019-01-09
AU2018241168A1 (en) 2018-11-01
NZ709986A (en) 2020-01-31
US10548872B2 (en) 2020-02-04
WO2014113700A1 (en) 2014-07-24
BR112015017241B1 (pt) 2021-10-26
DK3284463T3 (da) 2019-10-28
HRP20191919T1 (hr) 2020-01-10
AU2018203240B2 (en) 2019-12-12
CN105073105B (zh) 2018-02-27
LT2945620T (lt) 2018-02-12
CA2898443A1 (en) 2014-07-24
ES2659969T3 (es) 2018-03-20
US20210015784A1 (en) 2021-01-21
PT2945620T (pt) 2018-02-21
RU2015134583A (ru) 2017-02-22
US20140206769A1 (en) 2014-07-24
EP2945620B1 (en) 2017-11-22
NZ748771A (en) 2019-12-20
SG11201505567RA (en) 2015-09-29
RS58174B1 (sr) 2019-03-29
SI3284463T1 (sl) 2019-12-31
DK2945620T3 (en) 2018-02-05
AU2017200147B2 (en) 2018-07-05
WO2014113700A9 (en) 2014-10-09
IL239906A0 (en) 2015-08-31
AU2018203240A1 (en) 2018-05-31
CN110179777B (zh) 2022-07-15
US20190133990A1 (en) 2019-05-09
CN105142627A (zh) 2015-12-09
CY1121480T1 (el) 2020-05-29
EP2945621A1 (en) 2015-11-25
EP2945621B1 (en) 2018-10-17
SG10201913286PA (en) 2020-02-27
TWI712409B (zh) 2020-12-11
HRP20182144T1 (hr) 2019-03-08
US10245249B2 (en) 2019-04-02
IL239906B (en) 2018-05-31

Similar Documents

Publication Publication Date Title
MX2015009276A (es) Donadores de nitroxilo con indice terapeutico mejorado.
MX2016001037A (es) Inhibidores de factores de transcripción y usos.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
CA2956871C (en) Compounds active towards bromodomains
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX371017B (es) Inhibidores de dihidropirrolopiridina de receptor huerfano relacionado-gamma.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
PH12014501991B1 (en) Phenicol antibacterials
EA202090683A3 (ru) Способы и композиции для лечения рака
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
CL2015002897A1 (es) Inhibidores de bace1
EA201591698A1 (ru) Макроциклические ингибиторы киназы lrrk2
CA2929436C (en) Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
MX2017011018A (es) Inhibicion de la actividad de olig2.
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
MY186475A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
ZA201901367B (en) Inhibition of olig2 activity
WO2014146111A3 (en) Analgesic compounds and methods of use
EP3235808A4 (en) Modified taurine, and pharmaceutical composition for preventing or treating metabolic diseases containing same
EP3302487A4 (en) THERAPEUTIC COMPOSITIONS CONTAINING DIPYRIDAMOLE, MODULES AND TREATMENT KITS COMPRISING SUCH COMPOSITIONS, AND METHODS OF PRODUCING THE SAME
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.

Legal Events

Date Code Title Description
FG Grant or registration